Trump announces agreements with 9 major drugmakers to lower prices

The Trump administration announced agreements with nine major drugmakers to offer Medicaid-most-favored-nation (MFN) pricing and discounted medicines through a TrumpRx referral program, in exchange for three-year tariff exemptions; the White House said the deals include over $150 billion in U.S. investment commitments and cover treatments for chronic conditions. Participating firms include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi, while AbbVie, J&J and Regeneron were not included. Officials expect Medicaid price reductions and donations of active pharmaceutical ingredients to a strategic reserve, but experts note MFN may have limited impact for Medicaid beneficiaries due to existing statutory “best price” protections and exclusions for injectable/infusion drugs.

Analysis

Market structure: The deals transfer pricing pressure onto branded manufacturers that agreed to MFN commitments (AMGN, GILD, GSK, NVS, SNY, AZN, NVO, PFE) while leaving non‑participants (ABBV, JNJ, REGN) relatively advantaged. Expect 5–15% EBITDA downside on affected U.S. retail/institutional sales for those drugs over 12–24 months if MFN forces ~30–40% price convergence; manufacturers may offset with volume, formulary steering, or US manufacturing investments tied to the $150bn pledge. PBMs/insurers and state Medicaid budgets are winners (lower cash outflows); patients on Medicaid see little OOP change.

Risk assessment: Near term (days–weeks) the primary risks are legal/injunction outcomes and guidance revisions; a court block would reverse market moves quickly. Medium term (3–12 months) risks include companies delisting drugs from Medicaid or shifting rebates into list price structures, creating supply or access disruptions. Tail risks: broad application of MFN to commercial markets or international retaliatory pricing could cause 20–30% revenue shocks for exposed franchises; manufacturing reshoring promises may underdeliver and increase capex burden.

Trade implications: Tactical short exposure to high U.S. revenue sensitivity names (AMGN, GILD, NVO) versus longs in non‑participants (ABBV, JNJ) is attractive; size positions small (1–3% NAV) and time over 3–9 months. Use option structures: buy 3–6 month put spreads on AMGN/GILD (10%/20% strikes) to limit premium and sell covered calls on ABBV/JNJ to fund. Monitor CMS rule text and any DOJ/FTC guidance over next 30–90 days as primary catalysts.

Contrarian angle: Consensus overstates immediate cash pain because Medicaid “best price” already cushions many contracts; market could be overdiscounting near‑term earnings. Historical parallels (previous admin reference‑pricing attempts) show regulatory/ judicial pushback delays — if injunctions arrive, overcrowded shorts will squeeze. Unintended consequences (delisting, heavier reliance on list price offsets, R&D pullback) argue for concentrated, hedge‑protected positions rather than outright large directional bets.

Key Decisions for Investors

• Enter a 2% NAV short position in AMGN funded by a 2% NAV long in ABBV over 3–9 months; target a 15–30% relative move or spread widening of 200–300 bps; stop‑loss: close if ABBV/AMGN spread narrows by >10% in 30 days or if a federal injunction halts MFN within 60 days.
• Establish a 1–1.5% NAV position in 3–6 month put spreads on GILD (buy 10% OTM puts, sell 20% OTM puts) to profit from downside volatility while limiting premium; exit on 25% realized gain or on regulatory clarification from HHS/CMS.
• Deploy 1–2% NAV long in JNJ via covered calls (sell 6–9 month calls 10% OTM) to capture upside if non‑participants gain market share; roll or unwind if MFN is expanded to commercial payers within 6 months.
• Reduce small/mid‑cap specialty pharma exposure by 25–40% immediately; these firms face higher relative credit and supply risk—reallocate proceeds into large-cap defensive healthcare (JNJ, MRK) and selected muni/IG bonds with pharma exposure hedges over the next 4–12 weeks.
• Monitor three binary catalysts over next 60–120 days (1) final CMS MFN rule text, (2) any federal injunctions or court rulings, (3) company 2026 guidance revisions; if two occur adverse to MFN (injunction + guidance raise), close shorts and flip to long selective large‑cap names within 5 trading days.